Aa
A
A
A
Close
Hepatitis B Community
7.17k Members
Avatar universal

Ciclofilin Pharmaceuticals Invited to Present Hepatitis B Drug Data

SAN DIEGO, April 19, 2016 -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a privately held biotech, announced today that it will discuss important new data for its cyclophilin inhibitor, CPI-431-32, during a presentation at the Cambridge Healthtech Institute’s Eleventh Annual Drug Discovery Chemistry Conference to be held April 19-22, 2016 at the Hilton San Diego Resort in San Diego, CA. CPI-431-32 is Ciclofilin’s lead drug candidate for the treatment of hepatitis B virus (“HBV”) infection.

Ciclofilin’s CEO, Robert T. Foster, PharmD, PhD, will present findings that demonstrate CPI-431-32 is a best-in-class host-targeting antiviral drug. To date, CPI-431-32 in vitro completely suppresses HBsAg, suppresses HBeAg, and suppresses intracellular HBV DNA by greater than 90%, while also inhibiting viral uptake by blocking NTCP transporter activity. CPI-431-32 also reduces HBV DNA in the HBV1.3 transgenic mouse model. In contrast to other cyclophilin inhibitors, CPI-431-32 demonstrated a wide selective index (“SI”) as measured by the toxicity:efficacy ratio (CC50:IC50), which is sufficient for clinical development in HBV.

“We have almost three decades worth of experience in cyclosporine chemistry.  Drawing upon this experience in structure-activity relationships, we have learned that relatively small and selective changes to the chemical structure of the cyclosporine backbone can have very dramatic consequences in pharmacology,” commented Dr. Foster. “With that in mind, we have discovered a compound that has demonstrated a significant shift in both the efficacy against the hepatitis B virus and cytotoxicity profiles in a way that provides for a clear and meaningful separation of these two properties.  This degree of separation, known as selective index, is something we have not seen with other known cyclophilin inhibitors, making CPI-431-32 extremely unique and compelling.”

About Ciclofilin:
Ciclofilin is a privately held life sciences company based in San Diego, California, with R&D facilities in Edmonton, Canada. The company's lead oral drug candidate, CPI-431-32, is being developed as a treatment for chronic HBV infection. CPI-431-32 interferes with the ability of the HBV to infect cells, propagate, and cause disease primarily by preventing HBV interaction with host cell cyclophilins. CPI-431-32 also demonstrates anti-fibrotic activity in the liver, and may offer clinical benefits to patients in addition to anti-HBV activity.  CPI-431-32 has a wide selective index, allowing for HBV clinical development.
3 Responses
Avatar universal
.. and some poster from December 2015
http://www.ciclofilin.com/uploads/2/9/8/0/29800999/hepdart_2015_-__final_poster_dec_1_2015.pdf
Avatar universal
Ultimately everybody is waiting for that breakthrough in this area. Once the drug is approved, other research companies will start develop combos with thier own meds. Just recently, it was reported that a combo of certain HCV drugs can reduce treatment to only 6 weeks for acute infections.
1 Comments
that drug is quite interesting because it attacks virus in a few places, not only blocks replication like nucs
Avatar universal
exciting news! i hope it doesn't have bad side effects.
Have an Answer?
Didn't find the answer you were looking for?
Ask a question
Popular Resources
For people with Obsessive-Compulsive Disorder (OCD), the COVID-19 pandemic can be particularly challenging.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.
In You Can Prevent a Stroke, Dr. Joshua Yamamoto and Dr. Kristin Thomas help us understand what we can do to prevent a stroke.